Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $14.82 in the prior trading day, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) closed at $14.93, up 0.74%. In other words, the price has increased by $0.74 from its previous closing price. On the day, 0.5 million shares were traded. PHAT stock price reached its highest trading level at $15.1212 during the session, while it also had its lowest trading level at $14.61.
Ratios:
Our goal is to gain a better understanding of PHAT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.19 and its Current Ratio is at 2.23.
Upgrades & Downgrades
In the most recent recommendation for this company, Cantor Fitzgerald on February 14, 2025, initiated with a Overweight rating and assigned the stock a target price of $23.
On May 03, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $24. Needham reiterated its Buy rating for the stock on January 05, 2024, while the target price for the stock was revised from $23 to $26.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 03 ’25 when Breedlove Robert Charles sold 524 shares for $13.51 per share. The transaction valued at 7,079 led to the insider holds 47,407 shares of the business.
Breedlove Robert Charles sold 461 shares of PHAT for $5,573 on Sep 05 ’25. The Principal Accounting Officer now owns 47,931 shares after completing the transaction at $12.09 per share. On Jul 16 ’25, another insider, Breedlove Robert Charles, who serves as the Principal Accounting Officer of the company, sold 1,692 shares for $8.36 each. As a result, the insider received 14,152 and left with 48,392 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PHAT now has a Market Capitalization of 1062096960 and an Enterprise Value of 1510075648. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.22. Its current Enterprise Value per Revenue stands at 10.259 whereas that against EBITDA is -7.097.
Stock Price History:
The Beta on a monthly basis for PHAT is 0.42, which has changed by 0.6521739 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, PHAT has reached a high of $16.08, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is 14.41%, while the 200-Day Moving Average is calculated to be 72.44%.
Shares Statistics:
The stock has traded on average 1.14M shares per day over the past 3-months and 915690 shares per day over the last 10 days, according to various share statistics. A total of 71.04M shares are outstanding, with a floating share count of 41.32M. Insiders hold about 41.92% of the company’s shares, while institutions hold 50.73% stake in the company. Shares short for PHAT as of 1763078400 were 13078808 with a Short Ratio of 11.92, compared to 1760486400 on 14125695. Therefore, it implies a Short% of Shares Outstanding of 13078808 and a Short% of Float of 30.3.
Earnings Estimates
The stock of Phathom Pharmaceuticals Inc (PHAT) is currently being evaluated by 4.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.32 and low estimates of -$0.57.
Analysts are recommending an EPS of between -$2.09 and -$3.16 for the fiscal current year, implying an average EPS of -$2.41. EPS for the following year is -$0.16, with 4.0 analysts recommending between $0.4 and -$1.16.
Revenue Estimates
8 analysts predict $55.88M in revenue for . The current quarter. It ranges from a high estimate of $57M to a low estimate of $55M. As of . The current estimate, Phathom Pharmaceuticals Inc’s year-ago sales were $29.66MFor the next quarter, 8 analysts are estimating revenue of $59.94M. There is a high estimate of $66.89M for the next quarter, whereas the lowest estimate is $54.1M.
A total of 8 analysts have provided revenue estimates for PHAT’s current fiscal year. The highest revenue estimate was $174.53M, while the lowest revenue estimate was $172.5M, resulting in an average revenue estimate of $173.39M. In the same quarter a year ago, actual revenue was $55.25MBased on 8 analysts’ estimates, the company’s revenue will be $316.85M in the next fiscal year. The high estimate is $334M and the low estimate is $290M.
